ODTX · Nasdaq · USD · Market cap $1.1B · 100 employees
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.
FAIL · Does not pass the screenScreen close, 2026-09-22 · not a live quote
Last reviewed 13 days ago
Screened 2026-09-22 · the tape above runs as of 05:02 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
A price-versus-fair-value chart appears here once we hold enough history for this name.
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Odyssey Therapeutics, Inc. holds its Distribution at $23.34.
| Phase | Distribution · caution |
| Price at the screen | $23.34 |
| Valuation | N/A trailing · -5.35 forward price to earnings |
| Values screen | FAIL · score 70.0 |
Does not pass. Revenue purity
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 10.05% | Below 33% | Interest-bearing debt is just 10.0% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 13.05% | Below 33% | Cash held in interest-bearing accounts and securities is 13.0% of assets, under the one-third limit. | Pass |
| Receivables | 15.45% | Below 49% | Money owed to the company is 15.5% of assets, under the 49% limit. | Pass |
| Revenue purity | 100.00% | Below 5% | 100.0% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadOdyssey Therapeutics, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 100% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
What the Numbers Say It Is WorthFair value range in USD, drawn from the 2026-09-22 screen. The gold marker is the market price at the same screen. A 50.0% margin of safety to the base estimate.
Third-party analyst targets: 4 covering, consensus Strong Buy. The average target sits +50% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-22 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | -5.4x |
| EPS, trailing | -3.34 |
| EPS, forward | -4.36 |
| Profit margin | 0.0%currently unprofitable |
| Debt to equity | 0.06minimal debt: a conservative balance sheet |
| Current ratio | 11.36comfortably covers its short-term bills |
| Short interest, float | 0.05% |
| 52-week range | 15.10 - 29.05 |
| Market cap | $1.1B |
| Employees | 100 |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeODTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading bullish.
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading bullish.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
Screened names in the same industry · explore each on its own page.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $17.45 | -6.9% | · | $932 | -6.9% |
Historical returns from market close data. Past performance does not guarantee future results.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.
Get our weekly market brief free.